BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34687137)

  • 1. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
    Luzzago S; Piccinelli ML; Mistretta FA; Bianchi R; Cozzi G; Di Trapani E; Cioffi A; Catellani M; Fontana M; Jannello LMI; Botticelli FMG; Marvaso G; Alessi S; Pricolo P; Ferro M; Matei DV; Jereczek-Fossa BA; Fusco N; Petralia G; de Cobelli O; Musi G
    BJU Int; 2022 Apr; 129(4):524-533. PubMed ID: 34687137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
    BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
    Hsiang W; Ghabili K; Syed JS; Holder J; Nguyen KA; Suarez-Sarmiento A; Huber S; Leapman MS; Sprenkle PC
    Eur Urol Focus; 2021 Jan; 7(1):47-54. PubMed ID: 31147263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
    Beksac AT; Ratnani P; Dovey Z; Parekh S; Falagario U; Roshandel R; Sobotka S; Kewlani D; Davis A; Weil R; Bashorun H; Jambor I; Lewis S; Haines K; Tewari AK
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1492. PubMed ID: 34931468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer.
    Fujihara A; Iwata T; Shakir A; Tafuri A; Cacciamani GE; Gill K; Ashrafi A; Ukimura O; Desai M; Duddalwar V; Stern MS; Aron M; Palmer SL; Gill IS; Abreu AL
    BJU Int; 2021 Jun; 127(6):712-721. PubMed ID: 33043575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.
    Cussenot O; Renard-Penna R; Montagne S; Ondet V; Pilon A; Guechot J; Comperat E; Hamdy F; Lamb A; Cancel-Tassin G
    BJU Int; 2023 Jun; 131(6):745-754. PubMed ID: 36648168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
    Mamawala MK; Meyer AR; Landis PK; Macura KJ; Epstein JI; Partin AW; Carter BH; Gorin MA
    BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study.
    Valentin B; Arsov C; Ullrich T; Al-Monajjed R; Boschheidgen M; Hadaschik BA; Giganti F; Giessing M; Lopez-Cotarelo C; Esposito I; Antoch G; Albers P; Radtke JP; Schimmöller L
    Eur Urol Open Sci; 2024 Jan; 59():30-38. PubMed ID: 38298772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
    Hansen NL; Barrett T; Koo B; Doble A; Gnanapragasam V; Warren A; Kastner C; Bratt O
    BJU Int; 2017 May; 119(5):724-730. PubMed ID: 27488931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
    Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease.
    Greenberg JW; Koller CR; Lightfoot C; Brinkley GJ; Leinwand G; Wang J; Krane LS
    Urol Oncol; 2024 May; 42(5):158.e11-158.e16. PubMed ID: 38365461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI grading for the prediction of prostate cancer aggressiveness.
    Boschheidgen M; Schimmöller L; Arsov C; Ziayee F; Morawitz J; Valentin B; Radke KL; Giessing M; Esposito I; Albers P; Antoch G; Ullrich T
    Eur Radiol; 2022 Apr; 32(4):2351-2359. PubMed ID: 34748064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
    Chamorro Castillo L; García Morales L; Ruiz López D; Salguero Segura J; Valero Rosa J; Anglada Curado FJ; Mesa Quesada J; Blanca Pedregosa A; Carrasco Valiente J; Gómez Gómez E
    Prostate; 2023 Jun; 83(8):765-772. PubMed ID: 36895160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.